

Protecting Our Future

Contents

Protecting Our Future: Investment Opportunity 2026–2030.....	2
KEY MESSAGES	3
SOCIAL POST SUGGESTIONS.....	7
DIGITAL ASSETS	8
Infographics	8
Quote cards.....	8
RESOURCES	8
VOICES OF SUPPORT	8
Gavi, the Vaccine Alliance.....	9
African Vaccine Manufacturing Accelerator (AVMA).....	10

Protecting Our Future

Protecting Our Future: Investment Opportunity 2026-2030

Gavi's new [Investment Opportunity](#) (IO) outlines plans for the Vaccine Alliance to **protect 500 million children**, saving **over 8 million** lives between 2026 and 2030. While Gavi vaccinated 1 billion children between 2000 and 2020, Gavi will accelerate its impact in the years to come, leveraging the latest innovations in vaccines and vaccine delivery to **protect the next billion children in half the time as the first, and against more diseases, than ever before.**

Ask

- While Gavi vaccinated 1 billion children between 2000 and 2020, Gavi will **accelerate** its impact in the years to come, leveraging the latest innovations in vaccines and vaccine delivery **to protect the next billion children in half the time as the first, and against more diseases, than ever before.**
- Achieving this historic milestone will require effort from all of Gavi's stakeholders, **with donors being asked to provide funding of at least US\$ 9 billion in new funding.**

Pledges

- A number of new commitments and partnerships have been launched in support of Gavi's next strategic period, **totalling at least US\$ 2.4 billion:**
- In addition, a number of commitments were confirmed in support of the **African Vaccine Manufacturing Accelerator (AVMA)**, primarily through strategic reallocations of COVID-19 funding, totalling **approximately US\$ 1.2 billion.**
- In addition to financial commitments from sovereign and private donors to Gavi's next strategic period, and innovative private sector and philanthropic partnerships, vaccine manufacturers have also stepped up to support the Vaccine Alliance's goal of **shaping healthy vaccine markets that support equitable access.**
- These pledges will be supplemented by a suite of innovative finance instruments that will maximise the impact of donor pledges.

Investment Opportunity

A fully funded Gavi will enable the Alliance to achieve the following between 2026–2030:

- Immunise at least **500 million** more children
- Save an additional **8–9 million** lives
- Catalyse over **US\$ 4 billion** of financial contributions through **domestic co-financing** and **self-funded** vaccine programmes
- **Stand ready to respond to 150 disease outbreaks** to boost global health security and protect against the threat of future pandemics
- **Reduce prices** across at least **50%** of Gavi's vaccine portfolio, generate up to **US\$ 800 million** of **efficiency savings**
- Generate at least **US\$ 100 billion** in **economic benefits** for Gavi implementing countries
- Facilitate over **1.4 billion individual contacts** between families and health services, enabling **more integrated primary health care and Universal Health Coverage**
- Save **1.5 million** lives through the HPV vaccine by protecting girls against cervical cancer
- Vaccinate over **50 million children against malaria**

Protecting Our Future

African Vaccine Manufacturing Accelerator (AVMA)

The African Vaccine Manufacturing Accelerator (AVMA), launched 20 June 2024, is an innovative finance mechanism designed to improve Africa's resilience in the face of pandemics and other health emergencies. Designed in close collaboration with the AU, Africa CDC, G7 and G20, AVMA aims to offer at least **US\$ 1.2 billion** in incentives to the region's vaccine producers that successfully hit critical regulatory and supply milestones, helping to offset high upfront investment costs.

Visit the AVMA webpage: <https://gavi.org/avma>

Read the press release here: <https://www.gavi.org/news/media-room/protecting-more-children-gavi-vaccine-alliance-plans-next-5-year-period>

Gavi's Investment Opportunity 2026–2030

- **Investment Opportunity documents (English and French):** <https://www.gavi.org/investing-gavi/resource-mobilisation-process/protecting-our-future#io>
- Five years to save 8 million lives: everything you need to know about Gavi's Investment Opportunity: [link](#)
- Gavi's Investment Opportunity by numbers: [link](#)

KEY MESSAGES

1. Overarching messages:

- On 20 June 2024, leaders from government, civil society and business came together for [Protecting Our Future: The Global Forum for Vaccine Sovereignty and Innovation](#).
- Co-hosted by France, the African Union and Gavi, the Forum marked the beginning of a new era for sustainable vaccine manufacturing in Africa and set Gavi on a path towards its **most impactful period ever, vaccinating more children, against more diseases, faster than ever before**.
- The launch of the [African Vaccine Manufacturing Accelerator \(AVMA\)](#) at the Forum symbolises the power of the Gavi model as a broader ecosystem for innovative financing mechanisms to be designed and deployed to solve the world's pressing immunisation challenges.
- Supporting Gavi's replenishment sends a **message of hope**. A message to children that they can lead a healthy, fulfilled life; to countries that their economies can grow and that they can strengthen their health systems as well as health security globally; to people all over the world that international cooperation works, and that humanity can achieve far more by working together.

2. Gavi and AVMA: one ecosystem, solving the world's immunisation challenges

2.1 *Accelerating impact – Protecting our world, protecting people, protecting communities*

- Gavi is one of the most successful development initiatives in history, **protecting people and communities around the world**.

Protecting Our Future

- Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1 billion children – and prevented more than 17.3 million future deaths, helping to halve child mortality in 78 lower-income countries. Building on this success, Gavi will **accelerate** its impact in the years to come, leveraging the latest innovations in vaccines and vaccine delivery to protect the next billion children in half the time as the first, and against more diseases, than ever before.
 - *Proof point:* By 2030, Gavi's portfolio of vaccines will provide protection against more diseases than ever.
 - *Proof point:* Gavi's introduction and scale-up of vaccines for deadly diseases such as malaria and HPV vastly increase its potential for saving lives, protecting health systems and unlocking economic potential.
 - *Proof point:* IFFIm allows Gavi to deliver time-flexible funding to adapt to the changing timing of vaccine introductions and campaigns, and maximise the reach to zero-dose children.
 - *Proof point:* **AVMA** has been designed to ensure supplies of vaccines for countries that need them the most, and to boost supply of vaccines against which there are currently critical shortages, such as cholera, yellow fever, Ebola and meningitis.

2.2 A vital part of our world's health security system – Protecting the world

- Gavi has not only protected a whole generation of children from preventable diseases, **it has helped to protect our entire world** by preventing and responding to outbreaks of diseases that can so easily spread across borders.
 - *Proof point:* Through routine immunisation, Gavi helps to prevent outbreak-prone diseases such as measles.
 - *Proof point:* Thanks to Gavi's market shaping efforts, production of cholera vaccines has increased 18-fold in the last decade. Today, despite a massive surge in outbreaks in 2024, the Gavi-funded stockpile is fully replenished.
 - *Proof point:* By maintaining stockpiles for other outbreak-prone diseases such as Ebola, yellow fever and meningitis, Gavi is fighting on the front line to help keep deadly diseases at bay.
 - *Proof point:* As a co-lead of COVAX, Gavi helped deliver 2 billion COVID-19 vaccine doses to 146 countries during the pandemic.
 - *Proof point:* Innovative financing allows Gavi to protect the world faster by bringing future aid forward so it can have an impact today. Gavi accelerated its response to COVID-19 by frontloading over 90% of IFFIm COVAX pledges.
 - *Proof point:* IFFIm enabled Gavi's swift response to halt the 2014 Ebola crisis by providing standby funding, averting an outbreak from becoming a global pandemic.
 - *Proof point:* Gavi is helping the world prepare for future pandemics by creating the US\$ 2.5 billion **Day Zero Financing Facility**, making available up to US\$ 1 billion for **AVMA** and applying its dose sharing expertise to outbreaks of other diseases such as mpox.

Protecting Our Future

- *Proof point:* Facilities supported by **AVMA** will be able to be repurposed to produce vaccines in the event of a pandemic.

2.3 Sustainability is at the heart of Gavi's model

- The Vaccine Alliance places the countries it partners with in the driving seat.
 - *Proof point:* Interventions are designed specifically to enable countries to take on more and more ownership of their immunisation programmes as they grow and develop.
 - *Proof point:* Over the next five years, countries will make their largest ever investment in immunisation, paying over 40% of the costs of their routine vaccines.
 - *Proof point:* Since Gavi was established, 19 countries have transitioned from Gavi support as their per capita gross national income (GNI) levels have grown. One third of the original 73 Gavi-supported countries will have transitioned by 2030.
 - *Proof point:* As the latest innovative financing mechanism to be designed by Gavi, AVMA will play a formative role in helping build a high-quality, sustainable manufacturing sector capable of supporting the African Union's Platform for Harmonized African Health Products Manufacturing (PHAHM) ambition to manufacture at least 60% of the total vaccine doses required on the continent by 2040.

2.4 Driving health and growing economies

- Supporting Gavi is not just good for human health, it is also good for economic development, helping countries and families boost their income and enabling people's livelihoods to flourish and prosper.
 - *Proof point:* Every euro/dollar invested in Gavi generates 54 dollars/euros in wider economic benefits, making it among the best investments in development.
 - *Proof point:* By investing up to US\$ 1 billion in AVMA, Gavi is helping create a sustainable and high-value manufacturing sector for the African region, stimulating further investment across the entire vaccine value chain.
 - *Proof point:* Between 2021 and 2025 alone, Gavi's work will have generated over US\$ 80 billion of economic benefits for Gavi-supported countries.

2.5 A partner at the heart of global health

- As a public-private partnership, Gavi's unique model was always designed to unlock the comparative advantages of its broad array of stakeholders. In this same spirit of partnership, Gavi today works alongside new partners in ways that strengthen health systems, create efficiencies and open up entry points for other vital programmes, such as nutrition to reduce food insecurity.
 - *Proof point:* Empowering local actors and a **gender-focused** approach to immunisation will target hard-to-reach communities. Between 2026 and 2030, Gavi will facilitate hundreds of millions of contacts between families and health services through routine vaccination.
 - *Proof point:* Gavi and the Global Fund work together closely to enhance malaria prevention in sub-Saharan Africa, by ensuring access to all tools and interventions.

Protecting Our Future

2.6 An integral part of climate adaptation and AMR prevention

- As the climate crisis and rising antimicrobial resistance (AMR) continue to place great strain on the health systems of lower-income countries, vaccination is one of the strongest and most effective interventions. Half of Gavi's vaccine portfolio will help countries adapt and respond to these twin threats.
 - *Proof point:* Cholera, Japanese encephalitis, malaria, meningitis, typhoid and yellow fever are some of the climate-sensitive diseases in Gavi's portfolio.
 - *Proof point:* Gavi's efforts over the next strategic period can help turn the tide against AMR: Hib, pneumococcal, rotavirus and typhoid vaccination in Gavi-eligible countries could significantly reduce the use of antibiotics.
 - *Proof point:* Gavi works with countries to adapt routine immunisation programmes so they can be sustained through outbreaks and other health emergencies.
 - *Proof point:* With the help of IFFIm, Gavi can provide surge funding to respond to unexpected events, such as emergencies and outbreaks, which are more likely due to climate change.

2.7 Empowering women and supporting gender equality

- Tackling gender inequality means improving social, health and economic outcomes. In its next strategic period, Gavi will continue to sharpen its focus on gender to overcome barriers to access and help empower the predominantly female health care workforce.
 - *Proof point:* Millions of young women and girls will be protected from HPV between 2026 and 2030.
 - *Proof point:* Gavi is helping make health services more accessible and safer for women and girls; supporting the recruitment and training of women health workers and addressing their specific needs in the workplace; and providing services at times and places convenient for mothers, while also engaging fathers.
 - *Proof point:* Working directly with fathers in Togo has helped to reach more than 80% of children previously missing vaccination in targeted communities, while working with local and religious leaders in Papua New Guinea has improved the safety of women health workers.

2.8 Innovation, and value for money, is in Gavi's DNA

- AVMA is the latest example of how Gavi has used financial innovation and private sector innovation to address vaccine supply constraints, unlock new sources of funding for immunisation and deliver vaccines more effectively.
 - *Proof point:* In helping to set up the International Finance Facility for Immunisation (IFFIm), Gavi has unlocked US\$ 8.7 billion of funding through vaccine bonds.
 - *Proof point:* Through its Advance Market Commitments (AMCs) for pneumococcal and COVID-19 vaccines, Gavi incentivised vaccine production for lower-income countries that otherwise would have been left out of the marketplace.
 - *Proof point:* By partnering with innovators, Gavi has made breakthroughs in the use of drones and biometrics to improve last mile delivery of vaccines.

Protecting Our Future

SOCIAL POST SUGGESTIONS

- Investments in immunisation are investments in healthier futures for children around the world. The case for world leaders is clear: fully fund @Gavi #forourfuture <https://bit.ly/3KQTVMQ>
- Gavi's next strategic period up to 2030 calls for the world to invest, immunise and innovate #forourfuture. That's why we're supporting @Gavi's launch of their investment opportunity to usher in a new era of immunisation. <https://bit.ly/3KQTVMQ>
- Conflict, #climatechange and mass migration are fueling the risk of deadly outbreaks, which means the world needs @Gavi to be fully funded more than ever before. #ForOurFuture <https://bit.ly/3KQTVMQ>
- @Gavi's launch of their investment opportunity is a critical moment to highlight how funding immunisation secures healthier futures for children around the world. #VaccinesWork to protect communities, contain outbreaks and save lives. #ForOurFuture <https://bit.ly/3KQTVMQ>
- For every dollar invested in vaccination, \$21 is saved in health care costs, lost wages and lost productivity due to illness and death. As @Gavi launches their investment opportunity and usher in a new era of immunisation, we're calling for world leaders to fund lifesaving vaccines #ForOurFuture. <https://bit.ly/3KQTVMQ>
- Global immunisation efforts have saved at least 154 million lives over the past 50 years! We've seen what's #humanlypossible. Now it's time to build on this progress by fully funding @Gavi at their upcoming replenishment! <https://bit.ly/3KQTVMQ>

Humanly Possible

- Immunisation has saved six lives a minute. Every minute. For five decades. Now it's time for world leaders to invest in immunisation by fully funding @Gavi at their replenishment. #HumanlyPossible <https://bit.ly/3KQTVMQ>
- In the last 50 years, immunisation has decreased infant mortality by 40%. That means more children now reach their 5th birthday than ever before. World leaders must build on this incredible progress by funding @Gavi to invest in immunisation and show what is #HumanlyPossible <https://bit.ly/3KQTVMQ>
- Vaccines save lives and build futures. We're proud to work with @Gavi and together we have protected millions of children. But millions still miss out. It's time to look to the future and fully fund Gavi to invest in the future of immunisation. #HumanlyPossible <https://bit.ly/3KQTVMQ>

Protecting Our Future

Key hashtags

- #ForOurFuture
- #VaccinesWork
- #HumanlyPossible

DIGITAL ASSETS

Infographics

Infographics from Gavi's Investment Opportunity: [link](#)

Quote cards

Quote cards from countries, private sector, civil society and other partners: [link](#)

RESOURCES

MEDIA & CONTENT LIBRARY

- Photos from launch event: [link](#)
- Photos & B-roll of immunisation in action: [link](#)

VOICES OF SUPPORT

Why it matters: Voices of Support

Quotes and video content from heads of state, ministers, civil society and private sector leaders, and Alliance partners: [link](#)

Protecting Our Future

Gavi, the Vaccine Alliance

What is Gavi?

- Gavi, the Vaccine Alliance was established in 2000 as a **public-private partnership** that helps vaccinate more than half the world's children against some of the world's deadliest diseases.
- Gavi's mission is **to save lives and protect people's health by increasing equitable and sustainable use of vaccines.**
- Gavi plays a key role in **improving global health security** by supporting health systems and funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines.
- Gavi is focused on **protecting the next generation**, above all the zero-dose children who have not been reached by routine immunisation services.

What is Gavi's impact?

- **Helped to immunise over 1 billion children** since 2000 and has supported more than 1.8 billion vaccinations globally through preventive vaccination campaigns.
- **This has helped to reduce vaccine-preventable child deaths by 70%** in Gavi-supported lower-income countries; avert 17.3 million future deaths; and halve mortality among children aged under five.
- **An outbreak and pandemic response organisation supporting global health security:**
 - Global stockpiles for yellow fever, Ebola, cholera and meningococcal vaccines – with others planned
 - 2 billion COVID-19 vaccines to 146 economies helping avert an estimated 2.7 million deaths in AMC lower-income participating economies through COVAX
 - Day Zero Pandemic Financing Facility for Vaccines to ensure critical funding for future responses
- **Made vaccines more affordable and more accessible:** The cost of fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines has fallen by approximately 60% since 2010.
- **Supported 19 countries to transition** to fully self-financing their immunisation programmes. Over US\$ 1.5 billion in co-financing contributions from Gavi-supported countries since 2008.
- Protects against 20 infectious diseases, up from 6 during the 2001–2005 period.
- **Delivered US\$ 220.5 billion in economic benefits** through immunisation programmes in Gavi-supported lower-income countries.

What is Gavi's 2026–2030 Investment Opportunity?

- Gavi's Investment Opportunity (IO) outlines the **projected impact of the Alliance's programmes from 2026 to 2030 and how much funding is required to achieve these goals.**
- The IO looks at the number of children who could be vaccinated, lives that could be saved, growing number of diseases against which vaccines are now available and other factors such as:
 - Expanded stockpiles to cope with expected increases in disease outbreaks
 - Key emergency response mechanisms to contain emerging health threats
 - The impact of climate change
 - The economic benefits of immunisation
- **The Investment Opportunity makes the case to the global community, particularly donors, that investment in immunisation is one of the most cost-effective and impactful interventions for health and economic development.**

Protecting Our Future

African Vaccine Manufacturing Accelerator (AVMA)

What is AVMA?

- The [African Vaccine Manufacturing Accelerator \(AVMA\)](#) is an innovative financial mechanism, designed by Gavi in close collaboration with **Africa Centres for Disease Control and Prevention (Africa CDC)** with extensive consultations with partners, donors, industry, civil society and other stakeholders. AVMA aims to help vaccine manufacturers in Africa to scale up production and foster regional diversification of vaccine manufacturing.
- Africa accounts for around 20% of the world's population, yet the continent's vaccine industry provides only around 0.1% of global supply. AVMA will make a strong contribution to the African Union's **Platform for Harmonized African Health Products Manufacturing (PHAHM)** ambition to manufacture at least 60% of the total vaccine doses required on the continent by 2040, as well as the global effort to strengthen African health sovereignty at all times, including for pandemic preparedness and response.
- **With a commitment of up to US\$ 1 billion over ten years**, AVMA supports crucial development stages, offsetting high start-up costs. AVMA offers a 'pull financing mechanism' by providing downstream incentives to manufacturers to help offset initial costs of development and production.

For more information, please see the **African Vaccine Manufacturing Accelerator** announcement from December 2023: [AVMA: What is it and why is it important?](#)